Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug [Yahoo! Finance]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
The study of the drug troriluzole found a 50% to 70% slower rate of decline over three years for patients with spinocerebellar ataxia (SCA). The news sent Biohaven shares soaring 15% and moving into positive territory for the year. Biohaven ( BHVN ) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition. The company reported data collected over multiple analyses of its drug, troriluzole, showed "a robust and clinically meaningful slowing of disease progression" over a three-year period in patients with spinocerebellar ataxia, or SCA. Biohaven noted that SCA is a progressively debilitating neurodegenerative disease that affects some 15,000 people in the U.S. and 24,000 in Europe and the U.K., and there is no Food and Drug Administration (FDA) -approved medicine for it. Those Taking Drug Had 50% to 70% Slower Rate of Decline The research indicated those taking troriluzole had a
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- XVIVO Wins Two Davey Awards: A Gold and a Silver for Two Animation ProgramsPR Web
- Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at TD Cowen from $55.00 to $75.00. They now have a "buy" rating on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $66.00. They now have an "outperform" rating on the stock.MarketBeat
- Biohaven Non-GAAP EPS of -$1.74 misses by $0.24 Nov. 13, 2024 2:24 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]Seeking Alpha
BHVN
Earnings
- 11/12/24 - Miss
BHVN
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- BHVN's page on the SEC website